Mälardalen University

Digital literacy is defined as the ability to use information and communication technologies to find, evaluate, create and communicate information. This requires both technical skills to operate digital platforms, devices and apps, and cognitive skills for understanding and analysing the information being created. "About 40% of European citizens have problematic digital health literacy, which means that they cannot use digital health technologies adequately to address their health issues," says Sarah Wamala Andersson, professor of Health and Welfare Technology at the Mälardalen University in Sweden and a digital health thought leader. Wamala Andersson was among the researchers of the Improving Digital Empowerment for Active Healthy Living ( IDEAHL ) EU project aimed at developing and testing new models and approaches of digital health literacy intervention development. What interventions do we need for improved digital health literacy? The result of the IDEAHL project is the EU digital Health Literacy Strategy. The strategy defines concrete measures required on the micro, meso and macro levels. Key recommendations include the introduction of media literacy and information acquisition topics in primary school curricula on the micro level. These types of micro-level programs should lead to turning strategies into action. Apart from nurturing digital health literacy in basic education, cooperation between homes, schools and other educational institutions is encouraged. On the macro level, each country should create a centralised platform scientifically endorsed by the competent authority in each country to ensure people have access to reliable and comprehensive health resources, including informative articles, videos, interactive tools and forums for discussion and community support. Digital health literacy is a determinant of health In Europe, digital transformation is lagging in healthcare, compared with other industries. According to WHO , only one in two countries in Europe and central Aisa has policies to improve digital health literacy, implying that several millions of people are left behind. With the increasing use of technology for data gathering, care coordination, telemedicine and beyond, it is essential to ensure that digital access – or the absence thereof – does not widen the disparity between the healthy and the sick. "I can imagine that good health will be the most wanted good for many humans in the world, as AI and digital solutions make it possible to live along and enjoy a healthier life," Wamala Andersson said. "Thus, enhancing digital health literacy will become a natural part of the long-life learning initiatives, where governments will find it inevitable and beneficial to design and invest in policies and interventions that promote digital health literacy of the citizens, healthcare professionals and decision-makers." Sarah Wamala Andersson is among the speakers at the 2024 HIMSS European Health Conference & Exhibition, which is scheduled to take place 29-31 May 2024 in Rome. Learn more and register .

OSLO, Norway, Sept. 30, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX) announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax's Chemistry, Manufacturing, and Controls (CMC) program forward. Ola will be a member of Targovax's management team. Ola Melin joins Targovax with over 25 years' experience in Biologics development, manufacturing, and supply, most recently as Director of Technical Operations at OxThera AB, where he was responsible for clinical supply and for establishing a commercially ready manufacturing process and supply chain. Prior to that Ola spent eighteen years at Biovitrum and Sobi AB, where he held senior leadership roles as Head of External Manufacturing and Head of Product Supply, as well as other CMC positions. Ola started his career with manufacturing process development at Pharmacia. Ola has studied Biochemical engineering at Mälardalen University. Øystein Soug, CEO, commented, "It is with great enthusiasm we welcome Ola Melin to Targovax! With his broad experience with supply chain, clinical and commercial manufacturing, and his previous experience in launching products, he will bring important and valuable knowledge to Targovax. His CMC experience within the field of biologics development and manufacturing will contribute significantly to the execution of Targovax's strategic plan." Ola Melin added, "I am excited to join Targovax and be a part of the next development steps for its's lead clinical candidate ONCOS-102. The class-leading data in CPI refractory advanced melanoma, together with powerful immune activation, makes this an exciting product candidate and I look forward to contributing to the further development of this promising novel immune activator therapy that could make a huge difference to those diagnosed with cancer." Ola Melin will commence as Head of Manufacturing on 1st October. For further information, please contact: Oystein Soug, CEO Phone: +47 906 56 525 Email: oystein.soug@targovax.com Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no This information was brought to you by Cision View original content: SOURCE Targovax Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, Oslo:TRVX, RICS:TRVX.OL